Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Controlling alpha-cell glucagon secretion to optimize glycemic control
FY 2008-09
Summary
Background: In Type 1 Diabetes, glucagon secretion from islet alpha (a)-cells becomes progressively dysregulated. In early stage diabetes, a-cells hypersecrete to contribute to hyperglycemia; but in late stage diabetes, a-cells suffer from 'hypoglycemic blindness' resulting in life-threatening hypoglycemic attacks. No treatment has been developed to regulate glucagon secretion. The primary reason for the lack of insight into a-cell glucagon secretion is the very low-yield isolation and unreliable identification of islet a-cells, which severely impair the effective and efficient study of a-cell biology. We have surmounted these limitations by introducing green fluorescence protein (GFP) into mouse a-cells allowing a-cells to be visually distinguishable from other islet cell types. Furthermore, we employ the pancreas tissue slice preparation to preserve a-cells within their native cellular environment while examining these cells.
Objective: The goal of this proposal is to reliably examine glucagon-secreting pancreatic islet a-cell in health and in diabetes, from which we hope to determine novel therapeutic targets to better control glucagon secretion to alleviate its contribution to hypoglycemia in type 1 diabetes. Our first aim is to determine the underlying mechanism of glucose-inhibited glucagon secretion. Our second aim is to examine how paracrine factors released from the neighbouring islet cells inhibit glucagon secretion. Our third aim is to test the hypothesis that insulin released by b-cells is a prerequisite for "turning on/off" a-cell secretion.
Relevance to diabetes: We believe that the results arising from the experimentation of the 3 aims will answer these key questions about the a-cells in health and diabetes: 1) How does glucose regulate the a-cell? 2) How do the other islet cells (b- and d-cells) influence a-cell function? 3) How is this regulation in 1 and 2 distorted in diabetes (glucose blindness) and could this be reversed or rescued?
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
184533
Name
Huang Ya-Chi Karena
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Controlling alpha-cell glucagon secretion to optimize glycemic control
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Electrophysiology; Endocrinology; Exocytosis; Glucagon; Insulin; Mechanism Of Secretion; Pancreatic Alpha Cells; Pancreatic Beta Cells; Patch Clamping; Physiology
Abstract
Background: In Type 1 Diabetes, glucagon secretion from islet alpha (a)-cells becomes progressively dysregulated. In early stage diabetes, a-cells hypersecrete to contribute to hyperglycemia; but in late stage diabetes, a-cells suffer from 'hypoglycemic blindness' resulting in life-threatening hypoglycemic attacks. No treatment has been developed to regulate glucagon secretion. The primary reason for the lack of insight into a-cell glucagon secretion is the very low-yield isolation and unreliable identification of islet a-cells, which severely impair the effective and efficient study of a-cell biology. We have surmounted these limitations by introducing green fluorescence protein (GFP) into mouse a-cells allowing a-cells to be visually distinguishable from other islet cell types. Furthermore, we employ the pancreas tissue slice preparation to preserve a-cells within their native cellular environment while examining these cells.
Objective: The goal of this proposal is to reliably examine glucagon-secreting pancreatic islet a-cell in health and in diabetes, from which we hope to determine novel therapeutic targets to better control glucagon secretion to alleviate its contribution to hypoglycemia in type 1 diabetes. Our first aim is to determine the underlying mechanism of glucose-inhibited glucagon secretion. Our second aim is to examine how paracrine factors released from the neighbouring islet cells inhibit glucagon secretion. Our third aim is to test the hypothesis that insulin released by b-cells is a prerequisite for "turning on/off" a-cell secretion.
Relevance to diabetes: We believe that the results arising from the experimentation of the 3 aims will answer these key questions about the a-cells in health and diabetes: 1) How does glucose regulate the a-cell? 2) How do the other islet cells (b- and d-cells) influence a-cell function? 3) How is this regulation in 1 and 2 distorted in diabetes (glucose blindness) and could this be reversed or rescued?
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Huang, Ya-Chi Karena
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~